Research Updates

A 2026 review proposes that mitochondrial DNA released from damaged retinal cells may link oxidative stress, mitochondrial dysfunction, and inflammation in retinitis pigmentosa. Although it has not yet been measured in RP ocular fluids, extracellular mtDNA could become a valuable biomarker for tracking disease activity and testing treatments.

A ClinGen expert panel has developed RS1-specific rules to improve how genetic variants linked to X-linked retinoschisis are classified. In a pilot review of 54 variants, the framework updated 21 classifications and could strengthen future research and gene-based therapy development.

A 2026 study found that AI analysis of 2D and 3D facial photographs identified Stickler syndrome with up to 96% accuracy when focusing on the area around the eyes and nose. The approach could help reduce diagnostic delays and bring earlier attention to the condition’s serious retinal-detachment risk.

A 2026 natural-history study found that average macular sensitivity in Best vitelliform macular dystrophy changed little over about four years. However, microperimetry detected measurable decline in retinal locations that were normal at baseline, offering a potential outcome measure for future BVMD gene therapy trials.

A 2026 case report links retinitis pigmentosa with Coats-like retinal leakage, complex neurologic symptoms, and two FLVCR1 variants in a 31-year-old patient. The report highlights the value of integrated genetic, neurologic, and retinal care, while showing reduced lipid exudation after anti-VEGF treatment.

A new *Nature Communications* study maps the structure of the Kir7.1 potassium channel, which is linked to some forms of Leber congenital amaurosis. The findings provide molecular tools and insights that may support future research into KCNJ13-related retinal disease, while also highlighting Kir7.1’s roles beyond the eye.

Full-field stimulus threshold testing measures the dimmest full-field flash of light a person can detect, making it valuable when standard vision tests are unreliable. A 2026 review highlights its growing role in LCA research and gene therapy trials, while underscoring the need for standardized testing protocols.

High-resolution adaptive optics imaging has revealed disrupted cone organization in areas of RHO-associated retinitis pigmentosa that appear relatively preserved. The study also found greater rod disruption at the advancing disease edge and highlights cone-based measures as potential tools for future trials designed to preserve photoreceptor structure.

Researchers developed a light-based laboratory test that measures CYP4V2 enzyme activity after delivery of a Bietti crystalline dystrophy gene-therapy vector. The validated assay could support quality control, batch release, and stability testing for future rAAV-hCYP4V2 products.

A 2026 case report followed two siblings with Alström syndrome who received the SGLT2 inhibitor ertugliflozin for 11 months. Both had improved blood-glucose control, with early improvements in insulin resistance and favorable lipid changes; larger prospective studies are needed to define long-term benefits.

A 2026 case report describes two brothers diagnosed with both X-linked retinoschisis and X-linked ichthyosis, the first reported coexistence of these conditions. Genetic testing identified an RS1 variant linked to XLRS and an STS-region deletion linked to the boys’ skin symptoms, highlighting the value of comprehensive family evaluation.

The 2026 AXIS randomised trial found that oral acetazolamide did not meaningfully reduce cystoid fluid collections or improve most visual outcomes in people with X-linked retinoschisis. A modest improvement in retinal sensitivity and possible benefit in a small subset of participants support further research into personalised approaches.